Scary isn't it! 🎭

Open space ... not open skies what Trump defies ...

'Sapere aude'

Nice! Someone noticed ... 😉

'Sapere aude'

Ask your doctor for Remdesivir!

In an important moment for science and data transparency, @thelancet announces that its 96,000 observational study on hydroxychloroquine has been RETRACTED.

A sad story but an important one. https://t.co/qfPRsBDmP7 pic.twitter.com/GMDgP34tyb

— Jeremy Faust MD MS (@jeremyfaust) June 4, 2020

< wipes tears >

FX-arbitrage Phase
EU regulator recommends approving remdesivir as first Covid-19 treatment

The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 (€4,532) per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees (€59-€71).

The EMA endorsement, which comes just weeks after a speedy review, means physicians can prescribe the Gilead drug, to be branded Veklury, in Europe once approved by the European Commission, which usually follows CHMP recommendations.

archived Thu May 7th, 2020 MSRP

Diversity is the key to economic and political evolution.

Gilead remdesivir fire sale: "five-day treatment course at $2,340 per patient"

Drugmaker Gilead sets its price for the Covid-19 treatment remdesivir as HHS secures doses https://t.co/Eu9napRDAq

— POLITICO (@politico) June 29, 2020

while supplies last

Diversity is the key to economic and political evolution.

eBay "dutch auction", 325,600 minutes remaining

As Gilead charges $3,120 for its COVID drug, remdesivir, remember that the drug was developed with a $70,000,000 grant from the federal government paid for by American taxpayers.

Once again, Big Pharma is set to profit on the people's dime.

— Robert Reich (@RBReich) June 29, 2020

[emphasis added] Recall: USAMRIID (RDV; GS-5734); Gilead license "for the treatment of Ebola"

Diversity is the key to economic and political evolution.

Coup de grâce

The $2,300 price of a course of remdesivir may sound high - and is compared with the basic cost of manufacturing the stuff - but is actually fairly restrained. ...

< wipes tears >

Ahead of November's presidential election, the $94 billion pharma group's restraint may help it accumulate political capital.

wut

Diversity is the key to economic and political evolution.

scarce, precious fluids

The U.S. has bought nearly the entire global [!] supply of the antiviral drug remdesivir, the only treatment licensed to treat COVID-19, as the nation continues to experience surging cases of coronavirus.
[...]
The Trump administration announced this week the U.S. struck an agreement with Gilead to secure more than 500,000 treatment courses of the drug for American hospitals [!] through September.
[...]
Ohid Yaqub, a senior lecturer at the University of Sussex, called it disappointing news.

"It so clearly signals an unwillingness to cooperate with other countries and the chilling effect this has on international agreements about intellectual property rights," Yaqub said, according to the Associated Press [!].

< wipes tears >

[Andrew Hill, senior visiting research fellow at Liverpool University] told The Guardian that the UK could get access to remdesivir through a compulsory license, which overrides the intellectual property rights of the company. This would allow the UK to purchase from generic companies in Bangladesh or India where Gilead's patent is not recognized.

Gilead, June 29 price sheet

In the developing world, where healthcare resources, infrastructure and economics are so different, we have entered into agreements with generic manufacturers to deliver treatment at a substantially lower cost.

Mystery of Value Added to 79 rupees per "vial"

Diversity is the key to economic and political evolution.

Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19

Setting
The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan.

Participants
Consecutive patients hospitalized with a COVID-related admission in the health system from March 10,2020 to May 2,2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48 hours unless expired within 24 hours.

Exposure
Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.

Main Outcome
The primary outcome was in-hospital mortality.

Results
Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%])​. Primary cause of mortality was respiratory failure (88%);
[...]
Primary cause of mortality in the 460 patients was: 88% respiratory failure, 4% cardiac arrest (with mean QTc interval from last ECG reading 471 ms), 8% other cardiopulmonary arrest and multi-organ failure. No patient had documented torsades de pointes. ...

Diversity is the key to economic and political evolution.

Carsyn Leigh Davis

The Florida Department of Law Enforcement detailed the last two weeks of Carsyn's life in a public Medical Examiner's report.

Diversity is the key to economic and political evolution.